Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

September 6, 2017

Study Completion Date

September 7, 2017

Conditions
Infection, Human Immunodeficiency VirusHIV Infections
Interventions
DRUG

Cabotegravir

It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate

DRUG

Rifabutin

It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel

Trial Locations (1)

Unknown

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY

NCT03149848 - Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects | Biotech Hunter | Biotech Hunter